Systematic Review of Mendelian Randomization Studies on Antihypertensive Drugs

Overview

Journal BMC Med

Publisher Biomed Central

Specialty General Medicine

Date 2024 Nov 20

PMID 39567981

Authors

Bohan Fan

Junmeng Zhang

Jie V Zhao

Affiliations

Soon will be listed here.

Abstract

Background: We systematically reviewed Mendelian randomization (MR) studies and summarized evidence on the potential effects of different antihypertensive drugs on health.

Methods: We searched PubMed and Embase for MR studies evaluating the effects of antihypertensive drug classes on health outcomes until 22 May 2024. We extracted data on study characteristics and findings, assessed study quality, and compared the evidence with that from randomized controlled trials (RCTs).

Results: We identified 2643 studies in the search, of which 37 studies were included. These studies explored a wide range of health outcomes including cardiovascular diseases and their risk factors, psychiatric and neurodegenerative diseases, cancer, immune function and infection, and other outcomes. There is strong evidence supporting the protective effects of genetically proxied antihypertensive drugs on cardiovascular diseases. We found strong protective effects of angiotensin-converting enzyme (ACE) inhibitors on diabetes whereas beta-blockers showed adverse effects. ACE inhibitors might increase the risk of psoriasis, schizophrenia, and Alzheimer's disease but did not affect COVID-19. There is strong evidence that ACE inhibitors and calcium channel blockers (CCBs) are beneficial for kidney and immune function, and CCBs showed a safe profile for disorders of pregnancy. Most studies have high quality. RCT evidence supports the beneficial effects of ACE inhibitors and CCBs on stroke, diabetes, and kidney function. However, there is a lack of reliable RCTs to confirm the associations with other diseases.

Conclusions: Evidence of the benefits and off-target effects of antihypertensive drugs contribute to clinical decision-making, pharmacovigilance, and the identification of drug repurposing opportunities.

References

Zeng Y, Guo R, Cao S, Yang H . Impact of blood pressure and antihypertensive drug classes on intracranial aneurysm: a Mendelian randomization study. J Stroke Cerebrovasc Dis. 2023; 32(11):107355. DOI: 10.1016/j.jstrokecerebrovasdis.2023.107355. View

Ardissino M, Slob E, Rajasundaram S, Reddy R, Woolf B, Girling J . Safety of beta-blocker and calcium channel blocker antihypertensive drugs in pregnancy: a Mendelian randomization study. BMC Med. 2022; 20(1):288. PMC: 9446737. DOI: 10.1186/s12916-022-02483-1. View

Coleman C, Baker W, Kluger J, White C . Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. J Hypertens. 2008; 26(4):622-9. DOI: 10.1097/HJH.0b013e3282f3ef5e. View

Casas J, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani A . Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005; 366(9502):2026-33. DOI: 10.1016/S0140-6736(05)67814-2. View

Carey R, Moran A, Whelton P . Treatment of Hypertension: A Review. JAMA. 2022; 328(18):1849-1861. DOI: 10.1001/jama.2022.19590. View

Cunningham E, Todd S, Passmore P, Bullock R, McGuinness B . Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia. Cochrane Database Syst Rev. 2021; 5:CD004034. PMC: 8142793. DOI: 10.1002/14651858.CD004034.pub4. View

Walker V, Kehoe P, Martin R, Davies N . Repurposing antihypertensive drugs for the prevention of Alzheimer's disease: a Mendelian randomization study. Int J Epidemiol. 2019; 49(4):1132-1140. PMC: 7751008. DOI: 10.1093/ije/dyz155. View

Pigeyre M, Sjaarda J, Chong M, Hess S, Bosch J, Yusuf S . ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study. Diabetes Care. 2020; 43(4):835-842. DOI: 10.2337/dc19-1973. View

Ettehad D, Emdin C, Kiran A, Anderson S, Callender T, Emberson J . Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387(10022):957-967. DOI: 10.1016/S0140-6736(15)01225-8. View

10.

Xie W, Zheng F, Evangelou E, Liu O, Yang Z, Chan Q . Blood pressure-lowering drugs and secondary prevention of cardiovascular disease: systematic review and meta-analysis. J Hypertens. 2018; 36(6):1256-1265. DOI: 10.1097/HJH.0000000000001720. View

11.

Kazmi N, Valeeva E, Khasanova G, Lewis S, Plotnikov D . Blood pressure, calcium channel blockers, and the risk of prostate cancer: a Mendelian randomization study. Cancer Causes Control. 2023; 34(8):725-734. DOI: 10.1007/s10552-023-01712-z. View

12.

Wright J, Musini V, Gill R . First-line drugs for hypertension. Cochrane Database Syst Rev. 2018; 4:CD001841. PMC: 6513559. DOI: 10.1002/14651858.CD001841.pub3. View

13.

Nassan M, Daghlas I, Piras I, Rogalski E, Reus L, Pijnenburg Y . Evaluating the association between genetically proxied ACE inhibition and dementias. Alzheimers Dement. 2023; 19(9):3894-3901. DOI: 10.1002/alz.13062. View

14.

Xia K, Zhang L, Tang L, Huang T, Fan D . Assessing the role of blood pressure in amyotrophic lateral sclerosis: a Mendelian randomization study. Orphanet J Rare Dis. 2022; 17(1):56. PMC: 8848798. DOI: 10.1186/s13023-022-02212-0. View

15.

Dorhout Mees S, Rinkel G, Feigin V, Algra A, van den Bergh W, Vermeulen M . Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2007; (3):CD000277. PMC: 7044719. DOI: 10.1002/14651858.CD000277.pub3. View

16.

Zhu Y, Li M, Bai J, Wang H, Huang X . Hypertension, antihypertensive drugs, and age at onset of Huntington's disease. Orphanet J Rare Dis. 2023; 18(1):125. PMC: 10207760. DOI: 10.1186/s13023-023-02734-1. View

17.

van Middelaar T, Argillander T, Schreuder F, Deinum J, Richard E, Klijn C . Effect of Antihypertensive Medication on Cerebral Small Vessel Disease: A Systematic Review and Meta-Analysis. Stroke. 2018; 49(6):1531-1533. DOI: 10.1161/STROKEAHA.118.021160. View

18.

Nazarzadeh M, Bidel Z, Canoy D, Copland E, Wamil M, Majert J . Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. Lancet. 2021; 398(10313):1803-1810. PMC: 8585669. DOI: 10.1016/S0140-6736(21)01920-6. View

19.

Hughes D, Judge C, Murphy R, Loughlin E, Costello M, Whiteley W . Association of Blood Pressure Lowering With Incident Dementia or Cognitive Impairment: A Systematic Review and Meta-analysis. JAMA. 2020; 323(19):1934-1944. PMC: 7237983. DOI: 10.1001/jama.2020.4249. View

20.

Skrivankova V, Richmond R, Woolf B, Davies N, Swanson S, VanderWeele T . Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. BMJ. 2021; 375:n2233. PMC: 8546498. DOI: 10.1136/bmj.n2233. View